Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐label, single‐arm, Japanese phase 2 study was conducted to investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Masato, Masuda, Norikazu, Nishimura, Reiki, Inoue, Kenichi, Ohno, Shinji, Iwata, Hiroji, Hashigaki, Satoshi, Muramatsu, Yasuaki, Umeyama, Yoshiko, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367628/
https://www.ncbi.nlm.nih.gov/pubmed/32420697
http://dx.doi.org/10.1002/cam4.3091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367628/
https://www.ncbi.nlm.nih.gov/pubmed/32420697
http://dx.doi.org/10.1002/cam4.3091

Ejemplares similares